HYBRID EVENT: You can participate in person at Singapore or Virtually from your home or work.
2nd Edition of International Cancer & Immuno-Oncology Conference
March 19-21, 2026 | Singapore
Cancer Treatments
Cancer Treatments
- Surgical Oncology: Advances in minimally invasive surgery, robotic surgery, and complex resections.
- Medical Oncology: Chemotherapy, targeted therapies, and combination regimens.
- Radiation Oncology: Stereotactic radiotherapy, proton therapy, and new techniques.
- Immunotherapy: Checkpoint inhibitors, CAR-T cell therapy, and vaccine-based treatments.
- Combination Therapies: Synergistic effects of combining different modalities (e.g., chemo-radiation, immuno-oncology).
Advancements in cancer treatment have opened new doors for patients, providing more effective and tailored options. While traditional methods like surgery, chemotherapy, and radiation continue to play a crucial role, newer approaches are gaining ground. Targeted therapies focus on disrupting the specific molecular pathways that drive cancer growth, while immunotherapies harness the body’s immune system to better target cancer cells. Additionally, personalized medicine is revolutionizing treatment by customizing therapies based on the patient’s genetic makeup. Together, these innovations are transforming cancer care, offering greater hope for improved survival rates and quality of life.
Committee Members
Rajvir Dahiya
University of California San Francisco, United States
Atif A Ahmed
University of Washington-Seattle Children’s Hospital, United States
Thomas J Webster
Northeastern University, United States CIOC 2026 Speakers
Paulo Cesar De Morais
Catholic University of Brasilia, Brazil
Allen Chen
Olympic Medical Center, United States
Shilpa S Dhar
UT MD Anderson Cancer Center, United States
Ritu Khanna
University of Manchester, United KingdomSubmit your abstract Today
Title : A novel blood-based mRNA genomics technology for cancer diagnosis and treatment
Rajvir Dahiya, University of California San Francisco, United States
Title : Nanomedicine in humans: 30 years of fighting diseases
Thomas J Webster, Northeastern University, United States
Title : Diagnosis and treatment of primary cardiac lymphoma in an immunocompetent 27-year-old man
Moataz Taha Mahmoud Abdelsalam, Madinah Cardiac Center, Saudi Arabia
Title : tRNA-derived fragment 3′tRF-AlaAGC modulates cell chemoresistance and M2 macrophage polarization via binding to TRADD in breast cancer
Feng Yan, The Affiliated Cancer Hospital of Nanjing Medical University, China
Title : Multiplexed biosensor detection of cancer biomarkers
Michael Thompson, University of Toronto, Canada
Title : Personalized and Precision Medicine (PPM) through the view of biodesign-inspired translational research: An option for clinical oncologists, caregivers, and consumers to realize the potential of genomics-informed care to secure human biosafety
Sergey Suchkov, N.D. Zelinskii Institute for Organic Chemistry of the Russian Academy of Sciences, Russian Federation